Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk to cut 1,000 jobs as diabetes competition builds

Cites intensifying US market in particular for move to reduce costs
Novo Nordisk

The world's largest insulin producer Novo Nordisk has said it will cut 1,000 jobs over the next two months in a move to reduce operating costs.

President and chief executive Rebien Sørensen said: “We deeply regret that good colleagues stand to lose their jobs, and it has been a difficult decision to make.”

The lay offs are expected to hit the firm's research and development units, its headquarters staff and its global commercial organisation.

Novo, which employs 42,300 around the world, said that 500 of the planned job losses would take place in its home of Denmark.

The reductions come after increasing pressure in the diabetes market, with downward pricing and intensifying competition for market share affecting sales - particularly within the US.

Sørensen explained that the cuts are “needed in order for us to have a sustainable balance between income and costs”.

He added: “In the current situation, we have to prioritise investments in key product launches that will bring innovation to patients and drive our future growth.”

The company said in a statement that the workforce reduction will not change its financial outlook for the year, with Novo's half-year financial statement in early August reporting building momentum for its new basal insulin product Tresiba (insulin degludec).

Sales of the drug rose 161% to $216m (DKK 1.45bn) in the first six months of 2016, but it still has some way to go to compete with the $3.1bn (€2.86bn) brought in by Sanofi's established blockbuster Lantus (insulin glargine) during the same period.

Article by
Rebecca Clifford

29th September 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics